cellPhoresis®, enables non-destructive and rapid high resolution nanoscale bioAnalysis. cellPhoresis® in action: Field Based Infrastructure Management for Microbial Induced Corrosion, Non-Destructive Assessment of Vaccine Viability, Quality Testing of Microbial Ingredients for Food and Beverage (Yeast, Bacteria) to Predict Spoilage and Prevent Waste.
Existing tools to analyze microbes is costly, slow, and kills the microbes during the test. cBio bring a non-destructive, cost efficiency, and sensitive testing machine to the market.
Patented technology. 30 peer-reviewed publication. Performed 1 pilot with a CleanTech company, FREDSense®. Pilot setup with Merck that will begin in Q1 of 2020. Letter of Support from Thermo Fisher Scientific citing the value of our product.
CBio received $510,600.25 from FDA
CBio received $485,955.50 from FDA
CBio received $507,433.00 from OPM
CBio received $1,722,689.50 from FDA
CBio received $991,628.00 from OPM
CBio received $1,222,144.50 from FDA
CBio received $99,600.00 from FDA
| Agency | Total Amount |
|---|---|
| FDA | $4,040,989.75 |
| OPM | $1,499,061.00 |
| Total | $5,540,050.75 |
